Chemically Modified siRNA Delivery to Spinal Cord
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering small interfering RNAs (siRNAs) to the spinal cord face challenges such as low efficiency, instability in serum, and difficulties in crossing the blood-brain barrier, limiting their therapeutic effectiveness for treating spinal cord injuries and neuropathic pain.
Innovation Solution
The method involves administering double-stranded RNA compounds, including chemically modified siRNAs, directly to the spinal cord via intraparenchymal or lumbar injection to target specific genes like RhoA or TLR4, which are associated with neuropathic pain, without the use of transduction vehicles, allowing for localized treatment and potential recovery of motor functions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intrathecal delivery of siRNA is used, then treatment of spinal cord injury and neuropathic pain is achieved, but delivery efficiency is low and stability in serum is poor
Solution Approach 1:
The patent applies parameter changes by chemically modifying the siRNA molecules (e.g., phosphorothioate backbone modifications, 2'-O-methyl modifications) to alter their stability parameters. These chemical modifications increase serum half-life from minutes to hours, enabling effective intrathecal delivery while maintaining therapeutic effectiveness for spinal cord injury and neuropathic pain treatment.
2Productivity
If viral delivery is used, then cell transfection is achieved, but safety concerns arise
Solution Approach 1:
The patent extracts and eliminates the viral delivery system from the therapeutic approach. Instead of using viral vectors for transfection, the invention employs naked or chemically modified siRNA molecules that can directly enter cells through endocytosis or membrane fusion mechanisms, thereby maintaining transfection efficiency while removing all safety concerns associated with viral delivery.
Solution Approach 2:
The patent replaces complex viral delivery systems with simple, stable chemically modified siRNA molecules. These non-viral oligonucleotide therapeutics are easier to produce, lack the safety issues of viral vectors, and can be administered as stable formulations that maintain their activity without requiring complex delivery vehicles.
3Ease of operation
If cationic lipid-mediated transfection is used, then ease of delivery is improved, but transfection efficiency is low and cell specificity is limited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of siRNA molecules (e.g., adding ionizable groups, phosphorothioate modifications) to enhance their interaction with cell membranes. These modifications enable direct cellular uptake through endocytosis or membrane fusion without requiring cationic lipids, thereby improving transfection efficiency while maintaining ease of delivery and expanding cell specificity.
Data Source
AI summary
The present application relates at least in part to methods for the administration of small interfering RNAs (siRNAs) to the spinal cord of a human or animal patient and also to a method of treatment for spinal cord injury and other diseases and disorders of the CNS. In particular, the application discloses methods to deliver an siRNA compound locally, directly and without the need for transduction vehicles and formulations in effective doses to the injured spinal cord to promote recovery of CNS function and or attenuation of allodynia.